UCSF 12TH ANNUAL GYN CANCER SYMPOSIUM

CLINICAL TRIALS – WHAT TO EXPECT & HOW WE CAN HELP

9/28/2024

MEET THE RESEARCH TEAM

NATHALIE HALLEY
CLINICAL RESEARCH MANAGER (CRM)

CHETNA NANGIA
CLINICAL RESEARCH COORDINATOR (CRC)

CRYSTAL LEE
CLINICAL RESEARCH COORDINATOR (CRC)

HOW TO REACH US: GYNONCCLINICALTRIALS@UCSF.EDU

CRCS – OUR ROLE IN YOUR CARE

- CRCs are the point of contact for study related activities
- Help patients navigate clinical trials from the consent visit to the end of treatment
- Assist in scheduling infusion visits, clinical appointments, scans, and any research related activities
- Continue patient follow up after treatment ends
- Monitor patient side effects and track medications
- Serve as a liaison between patients and providers
- Answer any questions about clinical trials

FREQUENTLY ASKED QUESTIONS

- **What is a clinical trial & why is this being offered to me?**
  - Clinical trials are research studies that involve people in order to assist doctors in finding new ways to improve treatments and the quality of life for people with certain diseases.
- **After I sign the consent paperwork, when do I start?**
  - It takes about 3-4 weeks for a patient to complete all screening requirements of the trial prior to being approved to start treatment.
- **How often do I have to come to UCSF for trial?**
  - Office visits are generally required every 3-4 weeks. Depending on the trial, you may be asked to come more frequently for additional safety procedures or blood samples for the research study. CT/MRI Scans for the trial are often completed at every 6, 8, or 12 week intervals—these must also be completed at UCSF.
- **How long will I be on the trial for?**
  - Patients will stay on the clinical trial for the duration of their treatment—you will continue to receive the study drug as long as you are getting a benefit from it. After finishing treatment, most trials will want to follow patients until the study is complete. This is generally accomplished in a phone call from research staff to check in on how you are doing.



FREQUENTLY ASKED QUESTIONS

- **Will I get paid for being on trial?**
  - You will not be paid for taking part in a clinical trial
- **Will I get reimbursed for any trial related expenses?**
  - The sponsor may or may not offer to reimburse patients for expenses incurred while taking part. Travel reimbursement is commonly offered for gas, public transportation, and parking. Please ask your CRC if reimbursement is an option for a particular study.
- **Does insurance cover the cost of being on a clinical trial?**
  - Yes, insurances will cover the costs of procedures that are considered part of your routine care. While most plans cover clinical trials, it is your responsibility to check with them. Patients are responsible for all co-pays and deductibles according to their insurance plan. The clinical trial's sponsor pays for all research-related costs and any special testing.
- **What kinds of treatment can I expect to receive on a clinical trial?**
  - Clinical trials may offer chemotherapy, immunotherapy, or biomarker-driven therapy to patients.



FREQUENTLY ASKED QUESTIONS

- **Can I get my scans and labs done at my local doctor's office?**
  - While on clinical trial treatment, all trial-related procedures must be done at UCSF. Once you discontinue treatment, you may still need to come to UCSF for labs and other safety exams for 1-2 more visits.
- **What are the chances I get a placebo?**
  - It depends on the design of the study—not all clinical trials are placebo-controlled. If a placebo is part of the trial you're considering, you will be fully informed of that fact ahead of time.
- **If I start a clinical trial, can I change my mind later?**
  - Yes, participation in a clinical trial is always optional. Patients can withdraw participation at any time during the study.



OPEN GYN CLINICAL TRIALS

NRG-CC008: *A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]*

- NCT04251052

VIRGO: *Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)*

- NCT05523700

UAB 2031*: Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive*

- NCT04606914

AFT-50*: A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer [EndoMAP]*

- NCT04486352

GOG-3065 ZN-C3-004: *A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma [TETON]*

- NCT04814108

GOG-3097: *A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) [RAMP 301]*

- NCT06072781

ADDITIONAL RESOURCES

Where to find out more

NCT Website: https://clinicaltrials.gov/

NCI Website: https://www.cancer.gov/

UCSF Clinical Trials Finder: https://clinicaltrials.ucsf.edu/

HDFCCC Clinical Trials Decision Tool: ucsftrials.com